BeiGene and Ensem Therapeutics announced an agreement for BeiGene to acquire an exclusive global license to an Investigational New Drug application-ready oral cyclin-dependent kinase 2 inhibitor. Under the terms of the agreement, Ensem will receive an upfront payment, and will be eligible for additional payments upon the achievement of certain development, regulatory, and commercial milestones, totaling up to $1.33B, in addition to tiered royalties.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BGNE:
